The National Comprehensive Cancer Network announced the recipients of its 2022 awards.
The American Society of Hematology will recognize Judith Kleinerman as the recipient of the 2024 ASH Exemplary Service Award.
William Gradishar, Shonta Chambers, Robert Winn, Hema Sundar receive NCCN 2022 awards
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
Fred Hutch Cancer Center announced the recipients of the 2024 Dr. Eddie Méndez Scholar Award, which recognizes early-career scientists from underrepresented backgrounds who are studying cancer, infectious diseases, and basic sciences.
The National Comprehensive Cancer Network announced recognitions for the award-winning library of NCCN Guidelines for Patients and NCCN Patient Webinars.
The Cancer Letter staff were finalists for six 2024 Dateline Awards from the Washington, DC, Chapter of the Society of Professional Journalists—three for journalism, and three for design—and won first place for two.
